Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.

Chavez CL, Keravala A, Chu JN, Farruggio AP, Cuéllar VE, Voorberg J, Calos MP.

Hum Gene Ther. 2012 Apr;23(4):390-8. doi: 10.1089/hum.2011.110. Epub 2012 Jan 26.

2.

Long-term phenotypic correction in factor IX knockout mice by using ΦC31 integrase-mediated gene therapy.

Keravala A, Chavez CL, Hu G, Woodard LE, Monahan PE, Calos MP.

Gene Ther. 2011 Aug;18(8):842-8. doi: 10.1038/gt.2011.31. Epub 2011 Mar 17.

PMID:
21412285
3.

Kinetics and longevity of ΦC31 integrase in mouse liver and cultured cells.

Chavez CL, Keravala A, Woodard LE, Hillman RT, Stowe TR, Chu JN, Calos MP.

Hum Gene Ther. 2010 Oct;21(10):1287-97. doi: 10.1089/hum.2010.049.

4.

High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.

Xu L, Mei M, Ma X, Ponder KP.

J Thromb Haemost. 2007 Sep;5(9):1805-12. Epub 2007 May 21.

5.
6.

phiC31 integrase confers genomic integration and long-term transgene expression in rat retina.

Chalberg TW, Genise HL, Vollrath D, Calos MP.

Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2140-6.

PMID:
15914635
7.

Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, Patel N, Tuddenham EG, Christophe OD, McVey JH, Waddington S, Nienhuis AW, Gray JT, Fagone P, Mingozzi F, Zhou SZ, High KA, Cancio M, Ng CY, Zhou J, Morton CL, Davidoff AM, Nathwani AC.

Blood. 2013 Apr 25;121(17):3335-44. doi: 10.1182/blood-2012-10-462200. Epub 2013 Feb 20.

8.
9.

Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.

Peng B, Ye P, Blazar BR, Freeman GJ, Rawlings DJ, Ochs HD, Miao CH.

Blood. 2008 Sep 1;112(5):1662-72. doi: 10.1182/blood-2008-01-128413. Epub 2008 Jun 23.

10.

Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.

Ohlfest JR, Frandsen JL, Fritz S, Lobitz PD, Perkinson SG, Clark KJ, Nelsestuen G, Key NS, McIvor RS, Hackett PB, Largaespada DA.

Blood. 2005 Apr 1;105(7):2691-8. Epub 2004 Dec 2.

11.

Long-term hepatitis C internal ribosome entry site-dependent gene expression mediated by phage phiC31 integrase in mouse model.

Sun Z, Wang Y, Fu Q, Zhou Y, Jia S, Du J, Peng J, Wang Y, Yang S, Zhan L.

Antivir Ther. 2009;14(3):393-400.

PMID:
19474473
12.

PhiC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints.

Keravala A, Portlock JL, Nash JA, Vitrant DG, Robbins PD, Calos MP.

J Gene Med. 2006 Aug;8(8):1008-17.

PMID:
16779871
13.

Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.

Balagué C, Zhou J, Dai Y, Alemany R, Josephs SF, Andreason G, Hariharan M, Sethi E, Prokopenko E, Jan HY, Lou YC, Hubert-Leslie D, Ruiz L, Zhang WW.

Blood. 2000 Feb 1;95(3):820-8.

14.

Long-term in vivo gene expression in mouse kidney using φC31 integrase and electroporation.

Otani Y, Kawakami S, Mukai H, Fuchigami Y, Yamashita F, Hashida M.

J Drug Target. 2015 Jun;23(5):427-35. doi: 10.3109/1061186X.2014.1002788. Epub 2015 Feb 12.

PMID:
25673263
15.

Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.

Li YJ, Chen C, Zeng LY, Cao J, Xu KL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):658-63.

PMID:
22739177
16.

Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.

Chiang GG, Rubin HL, Cherington V, Wang T, Sobolewski J, McGrath CA, Gaffney A, Emami S, Sarver N, Levine PH, Greenberger JS, Hurwitz DR.

Hum Gene Ther. 1999 Jan 1;10(1):61-76.

PMID:
10022531
17.

Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.

Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, Herzog RW.

PLoS One. 2012;7(5):e37671. doi: 10.1371/journal.pone.0037671. Epub 2012 May 24.

18.

Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.

Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q.

J Thromb Haemost. 2012 Aug;10(8):1570-80. doi: 10.1111/j.1538-7836.2012.04791.x.

19.

Sustained expression of human factor VIII in mice using a parvovirus-based vector.

Chao H, Mao L, Bruce AT, Walsh CE.

Blood. 2000 Mar 1;95(5):1594-9.

20.

Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.

Sarkar R, Gao GP, Chirmule N, Tazelaar J, Kazazian HH Jr.

Hum Gene Ther. 2000 Apr 10;11(6):881-94.

PMID:
10779165

Supplemental Content

Support Center